The effect of biologic agents currently used for rheumatoid arthritis on the central nervous system of healthy rats by Panagiotopoulos, Spyridon et al.
Aristotle Biomedical Journal, Vol 1, No 2 e-ISSN: 2653-9748 
 
Copyright by author(s). This open-access article distributed under the terms of Creative Commons Attribution-NonCommercial 
4.0 International (CC BY-NC 4.0) See https://creativecommons.org/licenses/by-nc/4.0/ 
 
      Original article  
The effect of biologic agents currently used for rheumatoid arthritis on the 
central nervous system of healthy rats 
 
Panagiotopoulos Spyridon
1
, Ilia Tatiana- Soultana
1
, Tsotsolis Stavros
1
, Malliou 
Foteini
2
, Tsimoulas Ioannis
3
, Stamoula Eleni
4
, Poutoglidou Frideriki
5
, Kouvelas 
Alexios
6
, Papazisis Georgios
7
, Pourzitaki Chryssa
8
 
 
1
Medical Student, Faculty of Medicine, Department of Health Sciences, Aristotle 
University of Thessaloniki 
2
Post-Doctoral Researcher, Laboratory of Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
3
Medical Doctor, Pharmacist, Laboratory of Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
4
Biologist, Pharmacist, PhD, Laboratory of Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
5
Medical Doctor, PhD Candidate, Laboratory of Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
6
Chemistry Student, Faculty of Chemistry, Aristotle University of Thessaloniki 
7
Associate Professor of Pharmacology and Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
8
Assistant Professor of Pharmacology and Clinical Pharmacology, Faculty of 
Medicine, Department of Health Sciences, Aristotle University of Thessaloniki 
 
 
Abstract 
The aim of this study was to investigate the development of behavioral and memory 
disorders on healthy adult rats, after chronic, systematic administration of 
methotrexate and the biologic agents, Tocilizumab (anti-IL6) and Infliximab (anti-
TNFa), that are used for Rheumatoid Arthritis. 35 adult male Wistar rats, 12 weeks 
old, were used in this study. The rats were divided into 5 groups (n=7): a control 
group (CTRL), which was submitted to tests without receiving any drug, a placebo 
group (PLC) which received normal saline (i.p.), a methotrexate group (MTX) 
receiving 0.25mg/kg of the drug (i.p.), an infliximab group (INFL) receiving 6mg/kg 
of the drug (i.p.), and a tocilizumab group (TCZ) receiving 8mg/kg of the drug (i.p.). 
The drug infusion was performed weekly. After 30 days of drug administration, 
behavioral tests were performed to assess the rats’ stress levels and memory. The 
performed behavioral tests were (1) the Elevated-plus maze test, (2) the Elevated-zero 
maze test and (3) the Olfactory social memory test. The results were analyzed using 
Oneway-ANOVA and Kruskal-Wallis tests through SPSS 25.0. The MTX group 
spent significantly less time in the open arms of the mazes, compared to the CTRL 
group (P<0.001) and the PLC group (p=0.05), and needed less time during the second 
encounter compared to the first, when assessed in the olfactory social memory test 
(p=0.002). The TCZ and INFL groups spent more time in the open areas of both 
mazes compared to PLC and MTX groups (p=0.033). Based on the results of this 
study, the administration of biologic agents improves stress levels and shows a 
potentially anxiolytic effect, without significantly affecting memory. 
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Introduction 
Rheumatoid Arthritis (RA) is the most 
common rheumatic disease, affecting 
1% of the world’s population. It is a 
systemic autoimmune inflammatory 
disease whose mechanisms of 
pathogenesis include activation of T-
lymphocytes (CD4+) by an antigen and 
concomitant cytokine release, such as 
Tumor Necrosis Factor (TNFa-TNFb) 
and Interleukins (IL-1, IL-2, IL-4, IL-
6, IL-8). 
The drugs currently used for RA 
include non-steroidal anti-
inflammatory drugs (NSAIDs), 
glucocorticoids, classic disease 
modifying anti-rheumatic drugs 
(DMARDs), and biologic disease 
modifying drugs, which have been 
added to the therapeutic agent list this 
past decade. Some of the most widely 
used biologic disease modifying drugs 
are Infliximab (anti-TNFa) and 
Tocilizumab (Anti-IL-6), while a 
typical example of a DMARD is 
Methotrexate (Burmester and Pope, 
2017).  
Recent clinical trials have supported 
that DMARD and biologic agent 
therapy is associated with central 
nervous system (CNS) disorders. 
Specifically, Infliximab has been 
linked to demyelinating diseases 
(Optic neuritis, chronic inflammatory 
demyelinating polyneuropathy, 
Gulliain-Barré syndrome) (Caminero, 
Comabella and Montalban, 2011; 
Kaltsonoudis et al., 2014), while 
Tocilizumab, when co-administered 
with Methotrexate is believed to 
increase the risk of depression and 
anxiety disorders in patients with 
Rheumatoid Arthritis. (K. and U., 
2010; Pinho De Oliveira Ribeiro et al., 
2013) 
 
Aim of the study 
The widespread use of DMARDs has 
made the thorough investigation of 
their effect on different organ systems 
mandatory. This need is profound 
especially in their CNS effects, where 
research data is unclear. The aim of 
this study is to investigate the 
development of behavioral and 
memory disorders on healthy rats, after 
chronic, systemic administration of 
Methotrexate and biologic agents 
Infliximab and Tocilizumab. The 
above-mentioned mental functions are 
considered a good indicator of CNS 
activity and their disorders have been 
linked to numerous drug adverse 
effects. 
 
Materials and Methods 
Laboratory Animals and Subgroups 
Thirty-five (35) adult male Wistar rats 
were used in this study, all of them 
being 12 weeks of age. The rats were 
divided into 5 groups (n=7) as follows: 
a control group (CTRL), which was 
submitted to tests without receiving 
any drug, a placebo group (PLC) 
which received normal saline (i.p.), a 
methotrexate group (MTX) receiving 
0.25mg/kg of the drug (i.p.) (Bilasy et 
al., 2015), an infliximab group (INFL) 
receiving 6mg/kg of the drug (i.p.) 
(Karson et al., 2013), and a 
Tocilizumab group (TCZ) receiving 
8mg/kg of the drug (i.p.) (Taskin et al., 
2016). Drug infusion of the Placebo, 
MTX and INFL groups was performed 
weekly. The TCZ group received the 
drug every two weeks and during the 
in-between week the rats received 
normal saline. All infusions were 
performed intraperitoneally (i.p.), 
without the use of sedation. After 30 
days of drug administration, tests were 
performed to assess the rats’ sense of 
space, stress levels, memory and 
learning ability. 
 
Behavioral Tests 
The behavioral tests that were 
performed included the Elevated-plus 
maze test, (Braun et al., 2012) the 
Elevated zero maze test (Tucker and  
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Figure 1: Time spent in open arms during the Elevated Plus Maze test. Group CTRL= control 
(n=7), Group PLC=placebo (n=7), Group MTX=methotrexate (n=7), Group INFL=infliximab 
(n=7), Group TCZ=tocilizumab (n=7). Mean values ± SEM.  *P < 0.05; **P < 0.01, 
significantly different 
 
  
Figure 2: Time spent in the open arms during the Zero Maze test. Group CTRL= control 
(n=7), Group PLC=placebo (n=7), Group MTX=methotrexate (n=7), Group INFL=infliximab 
(n=7), Group TCZ=tocilizumab (n=7). Mean values ± SEM.  *P < 0.05; **P < 0.01, 
significantly different  
 
 
Figure 3: Ratio of First to Second exposure time in the Olfactory Social Memory Test. Group 
CTRL= control (n=7), Group PLC=placebo (n=7), Group MTX=methotrexate (n=7), Group 
INFL=infliximab (n=7), Group TCZ=tocilizumab (n=7). Mean values ± SEM.  *P < 0.05; 
**P < 0.01, significantly different  
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McCabe, 2017) and the Olfactory 
social memory test (Dantzer et al., 
1987). The Elevated-plus maze test 
was used to assess increased stress 
levels, in combination with memory. It 
is comprised of an elevated maze made 
of Plexiglas with two, white colored, 
open arms (each 45×10 cm) and two 
closed, black colored arms with the 
same dimensions. The elevated zero 
maze test was performed to assess 
stress and memory. It is comprised of 
an elevated, round maze made of 
Plexiglas, 65cm above the floor, with a 
diameter of 105cm which was split 
into quarters. Two of the quarters are 
open and two of them are closed. The 
open quarters of the maze have a 1cm 
high barrier on each edge to prevent 
rats from falling. The olfactory social 
memory test was used to assess 
memory disorders and investigate 
whether the differences found in the 
previous tests were caused by stress or 
memory impairment. All the above 
tests were performed between 14:00 
and 18:00, in standardized lighting, 
temperature and humidity conditions, 
in a dark testing room lit by a red-light 
emitting bulb. The data resulting from 
the above tests were analyzed using 
Oneway-ANOVA and Kruskal-Wallis 
tests through SPSS 25.0. 
Results 
The animals receiving TCZ and INFL 
spent a greater amount of time in the 
open areas of both mazes compared to 
PLC and MTX groups (p=0.033), 
(Figure 1 and Figure 2), while there 
was no statistically significant 
difference when comparing the results 
of the olfactory social memory test 
(Figure 3). The animals from the MTX 
group spent significantly less time in 
the open arms of the mazes compared 
to the Control group (p<0.001) and the 
Placebo group animals (p=0.05) 
(Figure 1 and Figure 2). Additionally, 
the animals receiving MTX needed 
less time during the second encounter 
compared to the first, when assessed in 
the olfactory social memory test. This 
result suggests that there was no 
memory dysfunction (p=0.002) (Figure 
3). 
 
Conclusion 
The animals received drug therapy for 
a period of 30 days. It is suggested that 
13,8 days in the lifespan of a rat are 
equivalent to a year in the life of a 
human. This means that the study 
mimicked a patient’s chronic exposure 
to these drugs, lasting longer than 2 
years (Sengupta et al. 2012). MTX 
infusion resulted in less time spent in 
the open arms of the mazes without 
affecting memory, a result that is 
justified by the reported adverse effects 
of the drug, even in patients receiving 
low doses. The results of the study 
showed that administration of biologic 
agents eased the stress caused by a 
stressful stimulus (exploration of the 
open arms of the mazes), without 
affecting memory. The effects of INFL 
and TCZ in the above behavioral tests 
suggest a potentially anxiolytic effect 
of these agents. 
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